2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. FGFR
  5. FGFR2 Isoform

FGFR2

FGFR2 encodes FGFR2b and FGFR2c isoforms with distinct expression domains and ligand specificity[1]. Mechanistically, FGF/FGFR signaling regulates lineage commitment, differentiation, proliferation, and apoptosis in development and adult homeostasis[2]. In disease models, FGFR2 alterations activate signaling in breast, gastric, cholangiocarcinoma, lung squamous, and oral squamous cancers[1][3][4]. Compared with related isoforms, FGFR2b-to-FGFR2c switching occurs during prostate and bladder cancer progression, linking splice regulation to epithelial-mesenchymal transition[1]. For experimental applications, FGFR2 mutation or amplification supports use of FGFR inhibitors, while extracellular-domain FGFR2 mutations can drive constitutive dimerization and inhibitor-sensitive transformation[1][4].

FGFR2 Related Products (3):

Cat. No. Product Name Effect Purity
  • HY-183780
    FGFR-IN-27
    		Inhibitor
    FGFR-IN-27 is an orally active, broad-spectrum FGFR inhibitor, with an IC50 of 0.24 nM against human FGFR1, 0.71 nM against FGFR2, 0.87 nM against FGFR3, and 6.50 nM against FGFR4. FGFR-IN-27 inhibits cancer cell proliferation and blocks tumor growth. FGFR-IN-27 reduces the phosphorylation levels of AKT and ERK, induces apoptosis and ferroptosis, increases ROS levels, and decreases GSH levels. FGFR-IN-27 can be used in the research of hepatocellular carcinoma.
  • HY-184250
    FGFR-IN-28
    		Inhibitor
    FGFR-IN-28 is a FGFR inhibitor with inhibitory activity against multiple subtypes of the FGFR family, with an IC50 of 4.4 nM against FGFR4. FGFR-IN-28 inhibits kinase activity and phosphorylation processes, and blocks the downstream MAPK and AKT signaling pathways. FGFR-IN-28 induces cellular DNA damage, cell cycle arrest, apoptosis and ferroptosis, and reduces the adhesion, invasion and metastasis abilities of cancer cells. FGFR-IN-28 exhibits anti-tumor activity in in vitro experiments on colon cancer cells, and inhibits tumor growth in colon cancer xenograft models. FGFR-IN-28 can be used in colon cancer-related research.
  • HY-10321G
    PD173074 (GMP)
    		Inhibitor
    PD173074 GMP is PD173074 (HY-10321) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. PD173074 is an orally active FGFR inhibitor that targets the transphosphorylation of FGFR1 and FGFR2 and blocks the FGF signaling pathway. By reducing the phosphorylation level of SMAD2 and altering the expression of Nodal/Activin target genes, PD173074 eliminates endothelial differentiation potential, thereby inhibiting the formation of capillary-like structures. PD173074 blocks the proliferation and colony formation of tumor cells and increases intratumoral cell apoptosis. PD173074 successfully reverses FGF-2-induced chemoresistance to enhance the effect of cisplatin (HY-17394) in small cell lung cancer models. PD173074 can be applied to research related to critical limb ischemia and small cell lung cancer.